Genta-Aventis Case Study: Failing Strategies Within Late Stage Vertical Licensing
| Format: | Electronic Journal |
|---|---|
| Language: | English |
| Published: |
MarketLine, a Progressive Digital Media business
|
| Online Access: | Full text available on EBSCOhost[Nov 2005-Nov 2005 |
Similar Items
IDEC-Genentech Case Study: Successful Late Stage Licensing Strategies
Roche-Kosan Case Study: Successful Early Licensing Strategies
Forest Laboratories & Schering-Plough Case Studies: Pharmaceutical Licensing Strategies
Aventis SWOT Analysis
Sanofi-Aventis Case Study: Building a Successful Insulin Portfolio
Sanofi-Aventis SWOT Analysis
Licensing Loyalty
by: McLeod
by: McLeod
License to Play
by: Daliot-Bul
by: Daliot-Bul
License to Wed
by: Richman
by: Richman
Licensing Journal
Failing Families, Failing Science
by: Lincoln
by: Lincoln
Licensed Practical Nurse
Vertical Reefs
by: Wicksten
by: Wicksten
Lipitor Case Study: Lifecycle Management Strategies
Failed Frontiersmen
by: Donahue
by: Donahue
Words Fail
by: Dickinson
by: Dickinson
The Revolution that Failed
by: Fairclough
by: Fairclough
Failed Evidence
by: Harris
by: Harris
Failed Promises
by: Konisky
by: Konisky
IPO Exit Strategies Case Study: Undertaking a Successful IPO Exit Strategy
Staging Harmony
by: Brokaw
by: Brokaw
Staging Asia
by: Kuruppath
by: Kuruppath
Setting the Stage
by: Hays
by: Hays
Subversive Stages
by: Komporaly
by: Komporaly
Staging Revolution
by: Fan
by: Fan
Occupying the Stage
by: Bredeson
by: Bredeson
Staging Family
by: Mullenneaux
by: Mullenneaux
Staging the Amistad
by: Christensen
by: Christensen
On Stage Alone
by: Gitelman
by: Gitelman
Staging Ghana
by: Schauert
by: Schauert
Stage for Action
by: Dail
by: Dail
The Stages of Memory
by: Young
by: Young
Similar Items
- IDEC-Genentech Case Study: Successful Late Stage Licensing Strategies
- Roche-Kosan Case Study: Successful Early Licensing Strategies
- Forest Laboratories & Schering-Plough Case Studies: Pharmaceutical Licensing Strategies
- Aventis SWOT Analysis
- Sanofi-Aventis Case Study: Building a Successful Insulin Portfolio